Pfizer Q1 Results Beat Expectations, Patent Extension Provides Cash-Flow Buffer

Overview

Pfizer reported first-quarter results in early May 2026, with both revenue and profit significantly exceeding market expectations. Management maintained its full-year guidance and, through the Vynda patent settlement, bolstered cash-flow certainty beyond 2029. However, attention has shifted to pivotal data from the company’s obesity and oncology pipelines, set to be unveiled at the ASCO and ADA conferences—findings that will determine whether Pfizer’s medium- to long-term growth thesis can be realized.

Core views

Earnings: Pfizer posted Q1 revenue of $14.5 billion, up 6% year-over-year and approximately 6% above consensus; adjusted EPS came in at $0.75, up 16% and roughly 16% above estimates. The upside largely stemmed from strong performance across Eliquis (+12%), oncology biosimilars (+56%), Abrysvo (+31%), Nurtec (+18%), Padcev (+10%), partially offset by steep declines in the COVID‑19 vaccine Comirnaty (-48%) and the oral antiviral Paxlovid (-28%). Guidance and Modeling: Management reiterated its full-year guidance of $59.5–$62.5 billion in revenue and adjusted EPS of $2.8–$3.0. Bernstein marginally raised its full-year revenue forecast by 1% to $61.2 billion, driven by stronger-than-expected demand for Eliquis, while lowering EPS to $2.92 primarily due to gross-margin pressure from a declining share of COVID‑related revenues. Patents and Cash Flow: In April, Pfizer reached a settlement in the Vynda patent litigation, extending U.S. exclusivity through June 2031, substantially mitigating the risk of a revenue cliff after 2029. Management projects high-single-digit compound annual growth rates for revenue between 2029 and 2033, creating room for sustained dividend payments and potential share repurchases. Pipeline Catalysts: In obesity, complete VESPER-3 data (weekly dosing switched to monthly) will be presented at the ADA meeting in June, along with details of the VESPER-6 monthly regimen; in oncology, interim data from the SV (sigvotatug vedotin) plus Keytruda combination, multiple datasets for the PD-1×VEGF bispecific PF-4404, and mid-stage results from the Phase III 2L NSCLC trial are scheduled for ASCO at the end of May, with final results expected around midyear. China GLP-1 Strategy: Pfizer is collaborating with Sciwind to commercialize ecnoglutide in China, with approvals for type 2 diabetes and weight-loss indications under review. The drug demonstrated 15.1% weight loss over 48 weeks, and the company emphasizes its advantages in primary-care channels.

Analysis framework

Bernstein employs a blended DCF–relative valuation framework, assigning 75% weight to multiples such as PE and EV/EBITDA and 25% to discounted cash flow. Core assumptions include a 7% WACC, a 0% terminal growth rate, and a 2026 target PE of 10x, below the long-term average of 11.3x. The model adopts a conservative scenario for COVID‑related revenues and assigns limited估值 to Metsera’s obesity assets pending further clinical validation.

Methodology notes

• Valuation MethodDCF Discounted Cash Flow

  The DCF model derives a company’s intrinsic value by forecasting future free cash flows and discounting them at the weighted average cost of capital

  The report uses a 7% WACC and 0% terminal growth rate in its DCF analysis, combining it with PE and EV/EBITDA multiples in a 25:75 weighting to arrive at a $30 price target

• Valuation MethodPE/PEG valuation

  Assessing a fair valuation range using the price-to-earnings ratio in conjunction with earnings growth

  The $30 target corresponds to a 2026 PE of 10x, below the historical average of 11.3x, reflecting caution about growth prospects

• Industry/Industrial Analysis FrameworkProduct life cycle

  Evaluating whether core products are in the growth, maturity, or decline phase to gauge revenue sustainability

  The report categorizes Comirnaty and Paxlovid as being in decline, Eliquis and Padcev as mature, and the early-stage obesity and oncology pipelines as in introduction

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Pfizer (PFE.US)

  Solid earnings and a patent extension provide a buffer, but growth still hinges on clinical data

  Strengths

  Q1 results beat expectations, Vynda patent extended to 2031, robust obesity and oncology pipelines, leading position in China’s GLP-1 market

  Weaknesses

  Continued decline in COVID‑related revenues, intensifying competition for mature products, uncertainty surrounding clinical data

  Comparison

  Current valuation trades below its historical average; positive clinical outcomes could unlock revaluation potential

  Risks

  Clinical data falling short of expectations, regulatory delays, worsening competitive dynamics

Key data

• Q1 Revenue14.5 billion USDUp 6% year-over-year, 6% above consensus
• Q1 Adjusted EPS0.75 USDUp 16% year-over-year, 16% above consensus
• Full-Year Revenue Guidance59.5–62.5 billion USDUnchanged
• Full-Year EPS Guidance2.8–3.0 USDUnchanged
• Price Target30 USDCorresponds to a 2026 PE of 10x
• Vynda Patent ExtensionThrough June 2031U.S. exclusivity extended by approximately two years
• Revenue CAGR for 2029–2033High single digitsManagement’s projection, contingent on Metsera’s success

Impact & implications

In the short term, Pfizer’s robust Q1 results and patent settlement reduce earnings volatility, providing support for the stock price; in the medium term, clinical data from the obesity and oncology pipelines will determine whether the company can move beyond reliance on mature products and upgrade its revenue mix; in the long term, the pace of volume ramp-up in China’s GLP-1 market and the global competitive landscape will be critical factors.

Risks

• Clinical data from the obesity and oncology pipelines failing to meet expectations
• COVID‑related revenues declining more sharply than anticipated
• Integration with Seagen and cost-cutting initiatives failing to deliver long-term growth
• Prevnar facing fierce competition from Merck

What to watch

• June ADA conference: Complete VESPER-3 data and interpretation of obesity strategy
• End of May ASCO: Interim data from SV plus Keytruda, multiple PF-4404 readouts
• Mid-2026: Mid-stage results from the SV 2L NSCLC Phase III trial
• Progress in the commercialization of ecnoglutide in China